Experienced, innovative biotech and pharma leader with demonstrated success in discovery and development of new therapeutic technologies

经验丰富，创新的生物技术和制药领导者，在发现和开发新的治疗技术方面取得了成功

AMSTERDAM, Dec. 5, 2023 /PRNewswire/ -- Kling Bio ('Kling' or 'the Company'), a biotech company developing antibody-based drugs against targets identified from its immortalized B-cell platform, is pleased to announce the appointment of Dr Stefano Gullà as Chief Scientific Officer.

阿姆斯特丹，2023年12月5日/PRNewswire/-Kling Bio（'Kling'或'the Company'），一家生物技术公司，开发针对从其永生化B细胞平台确定的靶标的基于抗体的药物，很高兴宣布任命StefanoGullà博士为首席科学官。

Dr Gullà is a seasoned industry veteran with over 15 years of experience in biotherapeutics discovery and development. Prior to joining Kling, Dr Gullà held senior positions at Pfizer, Agenus, Flagship, and RVAC where he led the discovery and development of its first-in-class therapeutics with applications in immuno-oncology and autoimmunity..

Gullà博士是一位经验丰富的行业退伍军人，拥有超过15年的生物治疗发现和开发经验。在加入Kling之前，Gullà博士在辉瑞，Agenus，旗舰和RVAC担任高级职位，在那里他领导发现和开发其一流疗法，并应用于免疫肿瘤学和自身免疫。。

Commenting on the appointment, Michael Koslowski, Chief Executive Officer of Kling Bio, said: 'Kling will benefit immensely from Stefano's proven leadership skills and in-depth scientific knowledge. I am confident Stefano will help guide and execute our vision for Kling during this pivotal phase of Company growth, as we accelerate to become a world-leading drug discovery and development company.'.

Kling Bio首席执行官Michael Koslowski在评论这项任命时说：“Kling将从Stefano成熟的领导技能和深入的科学知识中受益匪浅。随着我们加速成为世界领先的药物发现和开发公司，我相信Stefano将在公司成长的关键阶段帮助指导和执行我们对Kling的愿景。

Stefano Gullà, new Chief Scientific Officer of Kling Bio, commented: 'Kling's technology is a powerful discovery engine that enables simultaneous and unbiased identification of new targets and therapeutic antibodies. I am excited about the potential to scale this clinically proven platform, focusing on cancer and emerging infectious diseases, and look forward to working with Kling's exceptionally talented leadership team to continue building value for patients by advancing life changing medicines into the clinic.' .

Kling Bio的新首席科学官StefanoGullà评论说：“Kling的技术是一个强大的发现引擎，可以同时无偏见地识别新目标和治疗性抗体。我对扩大这个经过临床验证的平台的潜力感到兴奋，专注于癌症和新兴传染病，并期待与克林异常有才能的领导团队合作，通过将改变生命的药物推进临床，继续为患者创造价值 .

In addition to his successful track record of biotherapeutics discovery and development, Stefano brings exceptional entrepreneurial experience to Kling. In 2016, Stefano founded Abcuro, a biotech company focused on developing novel therapeutics for cancer and autoimmune diseases, where he held the positions of CEO and CSO.

除了他成功的生物治疗发现和开发记录外，Stefano还为Kling带来了卓越的创业经验。2016年，Stefano创立了Abcuro，这家生物技术公司专注于开发癌症和自身免疫性疾病的新疗法，并担任首席执行官和CSO的职位。

He led Abcuro from inception into the clinic and raised over $60 million in venture funding. Stefano is passionate about bringing innovative therapies to patients. He obtained a Bachelor of Science in Biochemistry and Doctor of Philosophy (Ph.D.) degrees from Northeastern University, before completing a postdoctoral training at the Massachusetts Institute of Technology (MIT)..

他领导Abcuro从一开始就进入诊所，并筹集超过6000万美元的风险资金。Stefano热衷于为患者带来创新疗法。他在麻省理工学院（MIT）完成博士后培训之前，获得了东北大学生物化学科学学士和哲学博士（博士）学位。。

About Kling Bio

关于Kling Bio

Kling Biotherapeutics is a clinical-stage, privately held biotech company focused on discovery and development of antibody based therapeutics. The company is headquartered in Amsterdam, Netherlands with a fully owned IP portfolio that covers platform technologies Kling-Select and Kling-Evolve for the simultaneous discovery of novel targets and identification of fully human antibodies directly from patient-derived B cells..

Kling Biotherapeutics是一家临床阶段的私营生物技术公司，专注于发现和开发基于抗体的疗法。该公司总部设在荷兰阿姆斯特丹，拥有完全拥有的IP组合，涵盖平台技术Kling Select和Kling Evolve，可同时发现新靶点并直接从患者来源的B细胞中鉴定全人抗体。。

Kling-Select relies on a fully-owned and clinically-validated B cell immortalization technology to identify novel therapeutic targets and antibody binders from patients with exceptional clinical responses. This technology has successfully identified novel neutralising antibodies for various infectious diseases such as RSV (nirsevimab/Beyfortus), Covid, and Influenza.

Kling Select依靠完全拥有和临床验证的B细胞永生化技术来鉴定具有特殊临床反应的患者的新型治疗靶点和抗体结合物。该技术已成功鉴定出用于各种传染病的新型中和抗体，如RSV（nirsevimab/Beyfortus），Covid和流感。

More recently, Kling-Select has been applied to peripheral and tumor-infiltrating B cells derived from cancer patients and produced a portfolio of novel and selective target-antibody pairs. The unbiased nature of this discovery platform allows identification of novel targets and unique epitopes inaccessible to traditional target discovery approaches..

最近，Kling Select已应用于源自癌症患者的外周和肿瘤浸润B细胞，并产生了一系列新颖且选择性的靶抗体对。该发现平台的无偏性质允许识别传统目标发现方法无法获得的新目标和独特表位。。

Kling-Evolve enables the ex vivo affinity maturation of B cell clones against targets of interest. This powerful technology can be used for the rapid evolution of neutralizing antibodies against emerging viral variants or for affinity and selectivity improvement of oncology assets.

Kling Evolve使B细胞克隆对目标靶标的离体亲和力成熟。这种强大的技术可用于快速发展针对新出现的病毒变体的中和抗体或用于肿瘤学资产的亲和力和选择性改善。

Kling Biotherapeutics is progressing a unique pipeline of oncology programs with KBA1412, a first-in-class CD9 antibody, being tested in a Phase 1 clinical trial.

Kling Biotherapeutics正在开发一种独特的肿瘤学项目，KBA1412是一流的CD9抗体，正在进行1期临床试验。

SOURCE Kling Bio

来源Kling Bio